Journal Home > Volume 6 , Issue 1

The retrospective study summarizes 28 years of cell therapy for neurotrauma of different origin. The four experimental groups were the groups of neurotrama that included traumatic disease of the spinal cord, traumatic disease of the brain and chronic vegetative post-traumatic state. The first group received transplantations of the fetal cells of neural tissue. The second group received the tissue engineering surgery with the transplantation of the fetal cells of neural tissue. The third group were the cases of the bioengineering pasty of the damaged brain tissue; and fourth were the cases of neurotrauma that were treated with the transplantation of the hematopoietic stem cells (HSCs) and hematopoietic precursor cells (HPCs). The long-term follow up proved the cell therapy with HSCs and HPCs to be the safest and most effective.


menu
Abstract
Full text
Outline
About this article

Translational experience of 28 years of use of the technologies of regenerative medicine to treat complex consequences of the brain and spinal cord trauma: Results, problems and conclusions

Show Author's information Andrey S. Bryukhovetskiy
NeuroVita Clinic of Restorative Interventional Neurology and Therapy, Moscow 115478, Russian Federation

Abstract

The retrospective study summarizes 28 years of cell therapy for neurotrauma of different origin. The four experimental groups were the groups of neurotrama that included traumatic disease of the spinal cord, traumatic disease of the brain and chronic vegetative post-traumatic state. The first group received transplantations of the fetal cells of neural tissue. The second group received the tissue engineering surgery with the transplantation of the fetal cells of neural tissue. The third group were the cases of the bioengineering pasty of the damaged brain tissue; and fourth were the cases of neurotrauma that were treated with the transplantation of the hematopoietic stem cells (HSCs) and hematopoietic precursor cells (HPCs). The long-term follow up proved the cell therapy with HSCs and HPCs to be the safest and most effective.

Keywords: cell therapy, cell transplantation, tissue engineering, spinal cord injury, stem cells, neurotrauma, hematopoietic stem cells, traumatic brain injury, long-term results

References(23)

[1]
Bryukhovetskiy AS. Spinal Cord Injury: Cell Technologies in the Treatment and Rehabilitation. (in Russian). Moscow, Russia: Prakticheskaya Meditsina, 2010.
[2]
Bryukhovetskiy AS. Transplantatsiya Transplantation of neural cells and tissue engineering of the brain and spinal cord in neural diseases. (in Russian). Moscow, Russia: ZAO Klinika vosstanovitelnoy interventsionnoy nevrologhii i terapii NeuroVita; 2003.
[3]
Bryukhovetskiy AS, Lavrentyev A, Zaisev A. Сell neurotransplantation in the complex treatment of damage spinal cord. Presented at the 4th International Conference High Medical Technologies in 21st Century. Spain, Benidorm, 2005.
[4]
Bryukhovetskiy AS, Zubritskiy VF, Chekhonin VP, et al. The method of bioengineering to restore the functions of the brain/spinal cord. The Russian Federation №2152038 RU.
DOI
[5]
Zhang C, Feng S, Hu N, et al. Osteopontin induces the extension of epidural fibrosis into the spinal canal (Letters to the Editor). Pain Physician. 2015, 18:E9-E99.
[6]
Abdelfatteh M, Mohamed B, Moncef BR, et al. Chapter 12. Spinal Cord Injury. In Neurorestoratology. Huang H, Raisman G, Sanberg PR, Sharma HS, editors. New York, USA: Nova Science Publishers, Inc, 2015.
[7]
Bryukhovetskiy AS. Information communicative organization of brain and its functional principles. Presented at IANR VII&1st SCSI with 11th GCNN & 2nd IFNR Conference, Mumbai, India, 2014 February 27–March 1.
DOI
[8]
Bryukhovetskiy AS, Avdeykin SN, Evseyev NG. Complications and specific features of the therapy of spinal cord injury with mobilized autologous haematopoietic stem and progenitor cells. Presented at the 21st Meeting of European Neurological Society, Lisbon, Portugal. 2011 May, 28–31. J. of Neurology. 2011, 258:Supplement1.
[9]
Bryukhovetskiy AS. Mobilized autologous stem cells in the SCI treatment. Journal of the Neurological Sciences. 2005, 238:S43.
[10]
Bryukhovetskiy AS, Dolgopolov R, Pimenov R, et al. PBSC mobilization and collection in patients with traumatic spinal cord. Bone marrow transpl.2005, 35, Suppl.2.
[11]
Bryukhovetskiy AS. Human Brain Theory. Information- Commutation Device of the Brain and Principles of its Work and Modeling. NewYork: Nova Science Publisher, 2016.
[12]
Bryukhovetskiy AS. Epigenetically reprogrammed cell systems of hematopoiesis precursor: From cell therapy to neurorestoration and neuroregulation of brain and spinal cord cells. Presented at IANRAC III. Beijing, China, April 23–25, 2010.
[13]
Bryukhovetskiy AS. Mobilized autologous stem cells from peripheral blood for the treatment of spinal cord injury (SCI). Efficacy and safety assessment. Presented at the 13th Congress of the European Federation of Neurology Societies. September 11–15, 2009; Florence, Italy. Eur J Neurol. 2009, 16(Suppl 3):302.
[14]
Chekhonin VP, Dmitriyeva TB, Krasheninnikov ME, et al. The method of production the preparation of the human neurons for cytotransfusion. The Russian Federation Patent No. 2146932 RU.
[15]
Bryukhovetskiy AS, Yarygin VN, Chekhonin VP, et al. Implantation of the biodegradable polymer matrix SpheroGel and embryonic stem cells under experimental complete spinal injury. Presented at the 7th International Congress of the Cell Transplant Society. Boston, USA, 2004.
[16]
Bryukhovetskiy AS, Polumbo O. Preparation of autologous non-hematopoetic progenitor stem cells, method of preparation and use thereof International Application № PCT/EP 2006/009008 filed September 15, 2006.
[17]
Tupitsin NN, Yaryghin VN, Grivtsova LY, et al. Immunophenotypic peculiarities of mobilized stem (CD34+) cells in blood from patients with severe spinal cord injury. J. of Biological Regulators and Homeostatic Agents. 2006, 20(1–2):36-40.
[18]
Bryukhovetskiy AS Myshkin OA, Avdeykin SN, et al. efficiency and safety assessment of 50 tissue engineering surgeries in spinal cord. Presented at the TERMIS-NA2010 Annual Conference, Orlando, USA, December 5–8, 2010.
[19]
Bryukhovetskiy AS, Myshkin O, Avdeikin S, et al. Fifty surgeries in tissue engineering of spinal cord injury with equivalent of artificial nervous tissue in humans. Presented at 2011 Translational Regenerative Medicine Forum, Washington, DC, USA, April 6–8, 2011.
DOI
[20]
Bryukhovetskiy AS, Yevseev N, Avdeykin S, et al. Comparative analysis of long-term outcomes of various stem cell therapies of spinal cord injury in humans. Presented at IANR V & 9th GCNN Conference with ISCITT Symposium, Xi’an, China, 4–7 May, 2012.
DOI
[21]
Bryukhovetskiy AS, Bryukhovetskiy IS. Remote multi‐ wave radioneuroengineering: An innovative technology for non‐contact radio restoration of damaged nervous tissue of the human brain and spinal cord. Translational Neuroscience and Clinics 2015, 1(1):1-29.
[22]
Bryukhovetskiy AS, Bryukhovetskiy IS. Effectiveness of repeated transplantations of hematopoietic stem cells in spinal cord injury. World J. Transplant. 2015, 5(3):110-128
[23]
Frolov AA, Bryukhovetskiy AS. Effect of hematopoietic autologous stem cell transplantation to the chronically injured human spinal cord evaluated by motor and somatosensory evoked potentials methods. Cell Transplant. 2012, 21(Suppl 1):S49-55.
Publication history
Copyright
Rights and permissions

Publication history

Received: 10 July 2018
Accepted: 17 September 2018
Published: 09 November 2018
Issue date: December 2018

Copyright

© The author(s) 2018

Rights and permissions

© The authors 2018. This article is published with open access at http://jnr.tsinghuajournals.com

Return